Three prognosis-related genes (HPRT1, ANP32B, and SNRPC) may serve as a set of potential biomarkers for evaluating the therapeutic efficacy of AZA/VEN treatment in AML patients. Here, ANP32B is linked to acute myeloid leukemia.